In July 2025, Community Health Systems made a transaction that illustrates an important shift taking place in the diagnostic laboratory industry.
The U.S. hospital group agreed to sell selected outpatient laboratory assets to Labcorp for US$195 million in cash.
But Community Health Systems was not exiting laboratory medicine.
Its affiliated hospitals would continue operating laboratories for inpatients and emergency departments, as well as laboratory services supporting hospital-based activities such as imaging and pre-admission testing.
What Labcorp was acquiring was different: selected assets from Community Health Systems’ ambulatory outreach laboratory business, including certain patient service centres and in-office blood collection locations across 13 U.S. states. The transaction was completed in December 2025 for approximately US$194 million before certain transaction expenses.
That distinction is important.
Hospitals need laboratory services to treat patients.
But that does not necessarily mean they need to own and operate every part of the laboratory value chain.
As healthcare systems face increasingly complex decisions about capital, technology and specialised diagnostics, some may decide that certain laboratory activities are better operated by a dedicated diagnostic company.
That creates an important question for healthcare investors:
What does a hospital truly need to own — and what could be performed more efficiently by a specialised partner?
Hospitals Are Not Selling Laboratory Medicine — They Are Separating Different Laboratory Functions
The phrase “selling a laboratory business” can be misleading.
A hospital laboratory performs several very different functions.
Some tests are directly connected to acute patient care.
An emergency department may need blood counts, cardiac markers or chemistry results within minutes or hours. Intensive care units require rapid laboratory support. Surgeons and inpatient physicians depend on immediate access to diagnostic information.
These services are strategically integrated into hospital operations.
Outreach laboratory services can be different.
An outreach laboratory may collect samples from physician offices, outpatient clinics, external patients or collection centres. Those samples can often be transported to another laboratory for processing without affecting immediate hospital care.
Community Health Systems’ transaction with Labcorp reflects exactly this distinction.
The health systems retained inpatient and emergency laboratory operations while transferring selected outpatient collection and outreach assets to Labcorp.
In other words, the question was not whether laboratories were necessary.
The question was which laboratory activities needed to remain inside the hospital system.
Why Would a Hospital Sell Its Outreach Laboratory Business?
There are several possible economic reasons.
The first is capital allocation.
Hospitals have many competing demands for investment: operating theatres, imaging equipment, intensive-care facilities, information technology, medical staff, new clinical programmes and hospital infrastructure.
Laboratory services also require continuous investment.
Analyzers need to be replaced.
Automation systems must be upgraded.
New molecular and genetic testing technologies require specialised equipment.
Information systems need integration and cybersecurity investment.
Specialised laboratory professionals must be recruited and retained.
A hospital therefore has to decide whether investing additional capital into an outreach laboratory network produces the best return compared with investing the same capital into core clinical services.
Labcorp itself says it expects hospitals, health systems and laboratories increasingly to focus investment on core patient-care services while seeking partners that offer comprehensive testing capabilities.
That does not mean this is necessarily the motive behind every laboratory transaction.
But it helps explain the broader strategic logic.
Scale Changes the Economics of Laboratory Testing
A second factor is scale.
Laboratory businesses have significant fixed infrastructure.
They require testing equipment, laboratory facilities, information systems, logistics networks, quality-management systems and trained technical personnel.
Once that infrastructure exists, processing additional samples can sometimes be economically attractive.
A large diagnostic company such as Labcorp can aggregate specimens from many hospitals, physician practices and patient service centres into a broader network.
Labcorp says its Diagnostics business operates a network of patient service centres and in-office collection sites supported by a supply chain that transports specimens across the testing process. Its systems also include more than 90,000 electronic interfaces connecting laboratory services with healthcare providers.
That scale can be difficult for an individual hospital system to reproduce.
For routine tests, the difference may be relatively small.
For highly specialised diagnostics, however, scale becomes much more important.
A hospital may only generate a limited number of certain oncology, genetic or molecular tests each month.
A national laboratory network can aggregate demand from thousands of healthcare providers.
The same specialised testing platform can therefore operate at much higher utilisation.
Specialised Testing Is Becoming More Complex
The economics of laboratory outsourcing become particularly relevant as diagnostic medicine becomes more sophisticated.
Modern diagnostic companies are moving beyond routine blood and urine testing.
Labcorp identifies oncology, women’s health, autoimmune disease and neurology as four major specialty-testing growth areas. The company also points to increasing adoption of biomarkers, earlier disease detection and personalised medicine as drivers of specialised testing demand.
These areas often require technology and expertise that are expensive to develop independently.
A hospital may have excellent clinical capabilities without needing to build every possible specialised laboratory platform internally.
Instead, it can retain the laboratory services essential to immediate patient care while sending selected tests to a specialist reference laboratory.
This creates a division of labour.
The hospital focuses on clinical care.
The diagnostic network focuses on testing scale, specialist capabilities, automation and laboratory logistics.
What Does Labcorp Gain?
For the diagnostic company, the transaction has a different attraction.
It gains existing testing volume.
That may be one of the most valuable assets in laboratory diagnostics.
Building a laboratory is relatively straightforward compared with building the network that feeds samples into it.
A diagnostic company entering a new market needs relationships with physicians, hospitals and clinics.
It needs patient collection locations.
It needs courier routes.
It needs digital connectivity.
And it needs sufficient testing demand to justify its infrastructure.
Acquiring an outreach laboratory business can provide much of this immediately.
Labcorp acquired selected Community Health Systems patient service centres and in-office phlebotomy locations across 13 states. Community Health Systems said the transaction would also provide patients and healthcare providers with access to Labcorp’s broader testing menu, specialty diagnostics, data analytics and digital tools.
So the transaction creates a potential exchange of value.
The hospital can simplify part of its laboratory operation.
Labcorp gains additional patients, providers and specimens for its existing network.
The Real Asset May Be the Network, Not the Equipment
This helps explain why laboratory businesses can become attractive M&A targets.
The physical analyzers are only part of their value.
An established outreach laboratory may also contain:
- relationships with physicians and clinics;
- recurring testing volumes;
- patient collection locations;
- trained employees;
- specimen transportation routes;
- information-system connections; and
- local market recognition.
For a large diagnostic platform, acquiring these relationships can be much faster than building them organically.
This is why laboratory consolidation is not simply a story about buying machines.
It is a story about buying access to testing volume.
Once that volume is connected to a larger platform, the acquiring company may be able to perform specialised tests elsewhere in its network, consolidate purchasing, improve equipment utilisation and introduce a broader diagnostic menu.
Sale Is Only One Possible Model
Hospitals also do not necessarily need to choose between fully owning a laboratory and completely selling it.
A range of partnership models is emerging.
A healthcare system could sell its outreach operations but retain inpatient testing.
It could outsource selected specialised tests.
It could create a joint venture with a diagnostic company.
It could retain ownership while allowing a specialist operator to manage laboratory operations.
Or it could establish a long-term strategic laboratory partnership.
Labcorp’s broader strategy reflects this flexibility.
In its 2025 annual report, the company said it signed or completed 13 collaboration transactions with health systems and regional or local laboratories during the year. It describes becoming a preferred partner to healthcare systems as one of its principal near-term growth strategies.
The company has also used models beyond straightforward acquisitions. In 2026, for example, Labcorp completed the acquisition of selected laboratory assets from Crouse Health while separately agreeing to manage Crouse’s inpatient laboratory operations.
That illustrates how flexible the boundary between hospital and independent laboratory operations can become.
What Could This Mean for Vietnam?
Vietnam’s healthcare market is structurally different from the United States, so the Community Health Systems transaction cannot simply be copied into the Vietnamese market.
But the underlying strategic question is relevant.
As Vietnamese hospitals expand and diagnostic technology becomes more sophisticated, management teams will increasingly need to decide where capital should be allocated.
Does every hospital need to own every molecular-testing platform?
Does every hospital need its own specialised genetics laboratory?
Does every outpatient collection point need to send samples to a laboratory owned by the same hospital?
Or could several hospitals share access to a specialised central laboratory operated by another organisation?
These questions become more important as diagnostics require greater investment in automation, technology, quality systems and specialist personnel.
For independent laboratory groups, that could create opportunities that go beyond competing directly with hospital laboratories.
The larger opportunity may be partnering with them.
Hospital Laboratories and Independent Laboratories May Become More Connected
The future diagnostic market therefore may not simply consist of two competing groups:
hospital laboratories versus independent laboratories.
The structure could become much more interconnected.
Hospitals may retain testing that is clinically urgent or strategically important.
Independent diagnostic networks may provide high-volume outpatient testing.
Reference laboratories may handle specialised diagnostics.
Collection networks may serve patients across multiple healthcare systems.
And partnerships may connect all of these functions.
Under this model, the competitive advantage shifts.
The winner is not necessarily the organisation that owns the greatest number of laboratories.
It may be the organisation that can connect hospitals, physicians, collection points, logistics and specialised testing infrastructure most efficiently.
The Strategic Question: What Should a Hospital Own?
Community Health Systems’ US$195 million agreement with Labcorp provides a useful example.
The hospital group did not abandon laboratory medicine.
It separated the parts of the laboratory business that were essential to hospital care from selected outreach activities that could become part of a larger diagnostic network.
That distinction could become increasingly important as healthcare becomes more capital intensive and diagnostics become more specialised.
For hospitals, the strategic question is no longer simply:
Should we have a laboratory?
Of course they should.
The more useful question is:
Which laboratory capabilities create the greatest strategic value when owned internally — and which could be delivered more efficiently through a specialised partner?
For diagnostic companies and healthcare investors, the answer could create an entirely new category of opportunities.
Not simply acquiring laboratories.
But redesigning who owns which part of the diagnostic value chain.